

I claim:

1. A therapeutic pharmaceutical composition, comprising an effective amount of camptothecin, or a camptothecin derivative, in combination with an effective amount of a topoisomerase II inhibitor for the treatment of solid tumors.
2. A therapeutic pharmaceutical composition, comprising an effective amount of CPT-11, in combination with an effective amount of a topoisomerase II inhibitor for the treatment of solid tumors.
3. The composition according to one of claims 1 or 2, wherein said topoisomerase II inhibitor is an anthracycline antibiotic.
4. The composition according to claim 3, wherein said antibiotic is doxorubicin.
5. The composition according to claim 3, wherein said antibiotic is daunorubicin.
6. The composition according to one of claims 1 or 2, wherein said topoisomerase II inhibitor is an epipodophyllotoxin.
7. The composition according to claim 6, wherein said epipodophyllotoxin is etoposide.
8. The composition according to claim 6, wherein said epipodophyllotoxin is teniposide.
9. The composition according to one of claims 1 or 2, wherein said solid tumor is a mammary adenocarcinoma.

10. The composition according to one of claims 1 or 2, wherein said solid tumor is a pancreatic ductal adenocarcinoma.

pub A2
11. A synergistic therapeutic pharmaceutical composition, comprising an effective amount at least two agents, wherein at least one agent is CPT-11, in combination with an effective amount of at least one second agent, wherein said second agent is doxorubicin, for the treatment of solid tumors.

12. The composition according to claim 11, wherein the at least two agents are administered simultaneously, semi-simultaneously, or separately.

pub A3
13. A method of treating a solid tumor, comprising administering an effective amount of camptothecin, or a camptothecin derivative, as a first agent, in combination with administration of an effective amount of a topoisomerase II inhibitor as a second agent, wherein the agents are administered simultaneously, semi-simultaneously, or separately.

14. The method according to claim 13, wherein the camptothecin derivative is CPT-11, and the topoisomerase II inhibitor is an anthracycline antibiotic.

15. The method according to claim 14, wherein said antibiotic is doxorubicin.

16. The method according to claim 14, wherein said antibiotic is daunorubicin.

17. The method according to claim 13, wherein the camptothecin derivative is CPT-11, and the topoisomerase II inhibitor is an epipodophyllotoxin.

18. The method according to claim 17, wherein said epipodophyllotoxin is etoposide.
19. The method according to claim 17, wherein said epipodophyllotoxin is teniposide.
20. The method according to any one of claims 13-19, wherein the camptothecin derivative is administered orally.

03806.0493-00000